Loading...

Acorda Therapeutics, Inc.

ACOR•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.66
$-0.21(-24.02%)

Acorda Therapeutics, Inc. (ACOR) Stock Overview

Explore Acorda Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.3/100

Key Financials

Market Cap821K
P/E Ratio-0.00
EPS (TTM)$-203.57
ROE1.43%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.19

ACOR Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Acorda Therapeutics, Inc. (ACOR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.19.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.00 and a market capitalization of 821K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for ACORStats details for ACOR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ACORAnalyst Recommendations details for ACOR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

CEO

Ron Cohen

Employees

102

Headquarters

420 Saw Mill River Road, Ardsley, NY

Founded

2006

Frequently Asked Questions

;